NCT04640714

Brief Summary

This research study is investigating an intervention called CONTINUity of care Under Management by Video visits (CONTINUUM-V). CONTINUUM-V involves a video visit with an oncology nurse practitioner within three business days of hospital discharge for patients with advanced cancer with the goal of reducing burdensome care transitions after hospitalization, including hospital readmissions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 11, 2020

Completed
12 days until next milestone

First Posted

Study publicly available on registry

November 23, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

January 7, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 28, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 14, 2021

Completed
Last Updated

November 19, 2021

Status Verified

November 1, 2021

Enrollment Period

5 months

First QC Date

November 11, 2020

Last Update Submit

November 11, 2021

Conditions

Keywords

Advanced CancerHome Care, Hospital-BasedTransitions of CareCare Transition Intervention

Outcome Measures

Primary Outcomes (1)

  • Feasibility using enrollment and retention on study

    The intervention will be deemed feasible if at least 70% of eligible patients participate in the study, and if at least 70% complete the video visit within three business days of discharge.

    Discharge to 3 business days

Secondary Outcomes (4)

  • Patients' Confidence in Managing their Health Condition using the Patient Activation Measure (PAM-13)

    Baseline to 15 days after discharge

  • Symptom Burden using the Edmonton Symptom Assessment Scale (ESAS-r)

    Baseline to 15 days after discharge

  • Psychological Symptoms using the Patient Health Questionnaire-4 (PHQ-4)

    Baseline to 15 days after discharge

  • Patient Satisfaction using the Patient Satisfaction Questionnaire

    10 to 15 days after discharge

Other Outcomes (1)

  • 30-day Hospital Readmissions

    Discharge to 30 days after discharge

Study Arms (1)

CONTINUity of care Under Management by Video visits (CONTINUUM-V)

EXPERIMENTAL

Participants with advanced cancer will receive a video visit conducted by an oncology Nurse Practitioner (NP) within three (3) business days of hospital discharge. The visit will involve: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team. Participant and clinician may also be interviewed for their feedback on the video visit. The ultimate goal of the intervention is to improve patients' confidence in managing their health condition and reduce burdensome health care utilization after discharge, particularly reducing 30-day hospital readmissions.

Behavioral: CONTINUity of care Under Management by Video visits (CONTINUUM-V)

Interventions

Video visit by nurse practitioner within 3 business days of hospital discharge.

CONTINUity of care Under Management by Video visits (CONTINUUM-V)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>= 18 years
  • Unplanned admission to the oncology service at Massachusetts General Hospital (MGH)
  • Known diagnosis of advanced breast, thoracic, genitourinary, or gastrointestinal cancers. Advanced cancer defined as not being treated with curative intent as determined by clinic notes and chemotherapy order entry.
  • Receiving ongoing oncology care at MGH
  • Verbal fluency in English
  • Must have internet/wifi/cellular data access

You may not qualify if:

  • Admitted electively
  • Discharged to a location other than home or expired during admission
  • Discharged with hospice services

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States

Location

Study Officials

  • Jennifer S Temel, MD

    Massachusetts General Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 11, 2020

First Posted

November 23, 2020

Study Start

January 7, 2021

Primary Completion

May 28, 2021

Study Completion

July 14, 2021

Last Updated

November 19, 2021

Record last verified: 2021-11

Data Sharing

IPD Sharing
Will share

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Data can be shared no earlier than 1 year following the date of publication
Access Criteria
Contact the Partners Innovations team at http://www.partners.org/innovation

Locations